Antiglycolytic Therapy Combined with an Image-guided Minimally Invasive Delivery Strategy for the Treatment of Breast Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Buijs, Manon | - |
dc.contributor.author | Wijlemans, Joost W. | - |
dc.contributor.author | Kwak, Byung Kook | - |
dc.contributor.author | Ota, Shinichi | - |
dc.contributor.author | Geschwind, Jean-Francois H. | - |
dc.date.available | 2019-03-09T01:58:31Z | - |
dc.date.issued | 2013-05 | - |
dc.identifier.issn | 1051-0443 | - |
dc.identifier.issn | 1535-7732 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/14666 | - |
dc.description.abstract | Purpose: The antiglycolytic agent 3-bromopyruvate (3-BrPA) promotes anticancer effects in multiple Minor models. This study evaluated the therapeutic efficacy of ultrasound (US)-guided intratumoral delivery of 3-BrPA in an orthotopic tumor model of breast cancer. Materials and Methods: Human breast cancer cell line MDA MB 231 was used for in vitro and in vivo studies. The anticancer effect of 3-BrPA was evaluated by viability assay, quantification of adenosine triphosphate (ATP) and lactate levels, and activity of matrix metalloproteinase (MMP)-9. In animal experiments, 15 nude mice with MDA MB 231 breast tumors were divided into three groups for US-guided intratumoral treatment with 1.75 mM 3-BrPA (group 1), 5 mM 3-BrPA (group 2), and saline solution (group 3): Tumor size was measured and subjected to histopathologic examination. Results: In vitro, treatment with 3-BrPA resulted in a dose-dependent decrease in cell viability. A decrease in ATP and lactate levels, invasion, and MMP9 activity and expression was observed after treatment with concentrations of 3-BrPA that did not affect cell viability. In vivo, a significant difference in tumor volume was observed between 3-BrPA-treated and control animals. At the end of the study, tumor volumes in the 3-BrPA groups were 1,876 mm(3) +/- 346 and 426 mm(3) +/- 180 in the 1.75-mM and 5-mM 3-BrPA groups, respectively, versus 4,447 mm(3) +/- 571 in the control group (P < .05). Conclusions: US-guided intratumoral injection of 3-BrPA effectively blocks breast cancer progression in an orthotopic mouse tumor model. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.title | Antiglycolytic Therapy Combined with an Image-guided Minimally Invasive Delivery Strategy for the Treatment of Breast Cancer | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.jvir.2013.01.013 | - |
dc.identifier.bibliographicCitation | JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, v.24, no.5, pp 737 - 743 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000318263500019 | - |
dc.identifier.scopusid | 2-s2.0-84876924193 | - |
dc.citation.endPage | 743 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 737 | - |
dc.citation.title | JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY | - |
dc.citation.volume | 24 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | 3-bromopyruvate | - |
dc.subject.keywordAuthor | 3-BrPA | - |
dc.subject.keywordAuthor | adenosine triphosphate | - |
dc.subject.keywordAuthor | ATP | - |
dc.subject.keywordAuthor | GAPDH | - |
dc.subject.keywordAuthor | glyceraldehyde 3-phosphate dehydrogenase | - |
dc.subject.keywordAuthor | H&E | - |
dc.subject.keywordAuthor | hematoxylin and eosin | - |
dc.subject.keywordAuthor | matrix metalloproteinase | - |
dc.subject.keywordAuthor | MEM | - |
dc.subject.keywordAuthor | MMP | - |
dc.subject.keywordAuthor | modified Eagle medium | - |
dc.subject.keywordAuthor | PBS | - |
dc.subject.keywordAuthor | PCR | - |
dc.subject.keywordAuthor | phosphate-buffered saline | - |
dc.subject.keywordAuthor | polymerase chain reaction | - |
dc.subject.keywordPlus | RADIOFREQUENCY ABLATION | - |
dc.subject.keywordPlus | CLINICAL-TRIAL | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | CARCINOMAS | - |
dc.subject.keywordPlus | 3-BROMOPYRUVATE | - |
dc.subject.keywordPlus | CRYOTHERAPY | - |
dc.subject.keywordPlus | MELANOMA | - |
dc.subject.keywordPlus | EXCISION | - |
dc.subject.keywordPlus | MMP9 | - |
dc.subject.keywordPlus | MRI | - |
dc.relation.journalResearchArea | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.